MedTrace Logo

Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)

NCT07459426 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 700

Last updated 2026-03-09

No results posted yet for this study

Summary

Chronic hepatitis B is a long-term viral infection that affects millions of people worldwide. Patients usually require lifelong antiviral treatment to control the virus and prevent liver damage.

Some older antiviral medications, such as lamivudine, can lead to the development of viral resistance. This means the virus changes in a way that makes certain treatments less effective. Even though newer drugs like entecavir are stronger and more resistant to these changes, previous exposure to lamivudine may increase the risk of developing additional resistance mutations.

By analyzing viral genetic material from blood samples using advanced sequencing technology, this research will help improve understanding of antiviral resistance patterns in patients with chronic hepatitis B in Turkey and may support better treatment decisions in the future.

Conditions

  • Hepatitis B, Chronic

Interventions

DIAGNOSTIC_TEST

Viral genetic material from blood samples using advanced sequencing technology

No intervention

Sponsors & Collaborators

  • SOUTHEAST NEUROLOGY AND INFECTIOUS DISEASES SOCIETY

    collaborator UNKNOWN

  • Yaşar Bayındır, MD

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-15
Primary Completion
2026-09-15
Completion
2027-03-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07459426 on ClinicalTrials.gov